Ovarian cancer xenograft tumor response to trastuzumab and pertuzumab
Analysis of SKOV3 ovarian cancer xenograft tumors treated with trastuzumab (TZ), pertuzumab (PZ), or both. TZ and PZ target Human Epidermal Growth Factor Receptor 2 (HER2). Combined therapy results in enhanced antitumor activity. Results provide insight into the molecular basis of this enhancement.
Cancer Type: Ovarian Cancer
GPL: 6947
Number of Genes with Data: 948
Number Observations: 23
Number Outputs: 1
Imbalanced Ratio: 0.833333333
Default Task: Classification